Nov. 14 at 12:41 PM
$TWST Twist Bioscience reports Q4 EPS (45c), consensus (50c)
-- Q4 revenue
$99.01M, consensus
$97.36M.
-- Sees Q1 revenue
$100M-
$101M, consensus
$100.75M
-- Sees FY26 revenue
$425M-
$435M, consensus
$434.81M
-- Sees FY26 gross margin above 52%.
"We ended the fiscal year with record revenue in the fourth quarter exceeding our guidance. By leveraging our technology, commercial execution and meeting the needs of our customers, we expanded our customer base and grew revenue 20% for the full fiscal year compared to the year prior," said Emily Leproust, CEO and co-founder of Twist Bioscience.
"As we enter fiscal 2026, we begin a new phase of growth for Twist, during which we expect to maintain gross margin above 50%, exit the fourth quarter of fiscal 2026 having achieved adjusted EBITDA breakeven and drive toward sustained and profitable growth."
